Sofinnova Partners, a European venture capital company specializing in life sciences, has recently closed its latest fund, Sofinnova Capital XI, at an impressive €650 million ($750 million), surpassing its initial target. The fund is designed to support early-stage healthcare companies in the US and Europe, with a particular focus on medical technology and biopharmaceutical ventures addressing unmet clinical needs.
The investment team at Sofinnova will leverage the expertise of partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi to identify and support promising startups in the healthcare sector. The fund will participate in both follow-on and initial rounds, continuing Sofinnova’s tradition of backing early-stage biotech and medtech companies across its core markets.
One of the key highlights of Sofinnova Capital XI is the diverse group of institutional investors who have committed to the fund. Foundations, corporates, family offices, insurance companies, sovereign wealth funds, and pharmaceutical companies from Europe, Asia, North America, and the Middle East have all shown interest in Sofinnova’s track record and investment strategy. The majority of returning limited partners, along with new investors, demonstrate continued confidence in the firm’s ability to deliver strong returns.
Managing partner and chairman Antoine Papiernik expressed his excitement about the successful fundraising, stating, “This milestone gives us the resources to double down on early-stage opportunities and continue our collaborative, science-driven investment approach. We are dedicated to supporting visionary entrepreneurs and driving innovation in science and medicine to benefit patients globally.”
Sofinnova Capital XI is already actively deploying capital, with investments in several portfolio companies underway. The firm’s focus on sustainability and healthcare, combined with its team’s diverse expertise in medicine, business, and science, positions Sofinnova as a key player in the life sciences venture capital space.
The original article, “Sofinnova closes €650m healthcare fund for early-stage ventures,” was published by Pharmaceutical Technology and provides additional insights into Sofinnova’s latest fund. For more information on this topic, you can refer to the original article on the Pharmaceutical Technology website.
Please note that the information provided in this post is for general informational purposes only and should not be considered as professional advice. It is recommended to seek expert guidance before making any investment decisions based on the content shared here.
